Clinical Trial: SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

This study is no longer recruiting patients.

Sponsors and Collaborators: University of Oxford
Merck
Information provided by: University of Oxford
ClinicalTrials.gov Identifier: NCT00124072

Purpose

SEARCH is a randomised, double-blind, multi-centre United Kingdom (UK) trial of 12,064 patients with myocardial infarction (MI) prior to study entry which aims to demonstrate whether a more intensive cholesterol lowering regimen using 80mg simvastatin daily produces a larger and worthwhile reduction in cardiovascular events compared with a standard 20mg daily regimen and whether reducing blood homocysteine levels with a daily dose of folic acid 2 mg + vitamin B12 1 mg compared with matching placebo produces a worthwhile reduction in vascular disease.
Condition Intervention Phase
Cardiovascular Disease
 Drug: Simvastatin (20mg versus 80mg daily)
 Drug: Folic acid 2mg + vitamin B12 1mg daily
Phase III

MedlinePlus related topics:  Heart Diseases;   Vascular Diseases

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Dose Comparison, Factorial Assignment, Safety/Efficacy Study

Further Study Details: 
Primary Outcomes: Major vascular events (MVE)
Secondary Outcomes: MVEs separately in year 1 and in later years; MVEs in patients subdivided into 3 groups by baseline low-density lipoprotein (LDL); MVEs in presence and absence of the other factorial treatment; Major coronary events; Total strokes
Expected Total Enrollment:  12064

Study start: July 1998

In observational studies, lower blood cholesterol concentrations are associated with lower coronary risk, without any clear threshold below which lower levels are not associated with lower risk. Cholesterol reduction with statins reduces such risk but there is uncertainty about whether greater reductions with more intensive statin therapy will produce greater benefits. Elevated blood homocysteine levels appear to be an independent marker of cardiovascular risk, but it is unknown whether taking vitamins to reduce homocysteine concentrations will translate into cardiovascular benefit.

12,064 survivors of myocardial infarction have been randomised in a 2x2 factorial design to more intensive versus standard cholesterol-lowering treatment, using 80mg or 20mg daily simvastatin, and separately to homocysteine-lowering with folic acid plus vitamin B12 or matching placebo. Follow-up will continue until there are at least 2800 confirmed major vascular events (MVE), defined as non-fatal myocardial infarction, coronary death, stroke or arterial revascularisation. The primary outcome is the incidence of first MVE during the scheduled treatment period.

SEARCH should provide reliable evidence of the effectiveness and safety of more intensive cholesterol-lowering for the reduction of major vascular events in a high-risk population, and of the effects of homocysteine-lowering with folic acid plus vitamin B12.

Eligibility

Ages Eligible for Study:  18 Years   -   80 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • Prior myocardial infarction
  • Statin therapy indicated
  • No clear indication for folic acid

Exclusion Criteria:

  • No clear contraindication to study treatments
  • Screening plasma total cholesterol <3.5 mmol/l in patient already on statin therapy, or <4.5 mmol/l in patient not on statin therapy
  • Chronic liver disease
  • Severe renal disease or evidence of renal impairment
  • Inflammatory muscle disease
  • Concurrent treatment with fibrates or high-dose niacin
  • Concurrent treatment with cyclosporin (or condition likely to result in organ transplantation and the need for cyclosporin), nefazodone, methotrexate, systemic azole antifungal or systemic macrolide antibiotics
  • Child bearing potential
  • No other predominant medical problem (other than coronary heart disease [CHD]) which might limit compliance with 5 years of study treatment

Location Information


United Kingdom, Oxon
      CTSU, Richard Doll Building, University of Oxford, Oxford,  Oxon,  OX3 7LF,  United Kingdom

Study chairs or principal investigators

Rory Collins, MB BS FRCP,  Study Director,  University of Oxford   

More Information

Study ID Numbers:  CTSUSEARCH1
Last Updated:  August 4, 2005
Record first received:  July 22, 2005
ClinicalTrials.gov Identifier:  NCT00124072
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
ClinicalTrials.gov processed this record on 2005-08-23

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Contact Us

Follow Us